Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Pulmonary embolism: current treatment options.

Marc Meysman1, Patrick Haentjens

  • 1Respiratory Division, Department of Medicine, University Hospital VUB, Vrije Universiteit Brussel, Laarbeeklaan 101, Brussels B-1090, Belgium.

Current Treatment Options in Cardiovascular Medicine
|November 15, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Belgian consensus on sotatercept for the treatment of pulmonary arterial hypertension.

Acta cardiologica·2024
Same author

A swollen face and neck after dental surgery: Think of subcutaneous emphysema and pneumomediastinum.

Respiratory medicine case reports·2023
Same author

Peak Inspiratory Flow for Screening of Inspiratory Muscle Weakness in Neuromuscular Disease.

Lung·2023
Same author

Heart failure with preserved ejection fraction: relevance of a dedicated dyspnoea clinic.

European heart journal·2023
Same author

The effect of nicotine patches on craving in the brain: A functional MRI study on heavy smokers.

Medicine·2018
Same author

Factors determining altered perfusion after acute pulmonary embolism assessed by quantified single-photon emission computed tomography-perfusion scan.

Annals of thoracic medicine·2017

Low molecular weight heparins are increasingly used for acute pulmonary embolism treatment due to predictable effects and simpler dosing. Novel anticoagulants show promise but are not yet standard for initial pulmonary embolism care.

Area of Science:

  • Cardiology
  • Hematology
  • Pharmacology

Background:

  • Acute pulmonary embolism (PE) management traditionally used unfractionated heparin.
  • Low molecular weight heparins (LMWHs) offer predictable pharmacokinetics and simpler dosing, leading to their wider adoption.
  • Exceptions for LMWH use include obese patients and those with renal failure.

Purpose of the Study:

  • To review current and emerging treatment strategies for acute pulmonary embolism.
  • To compare the efficacy and administration of various anticoagulant therapies.
  • To outline indications for advanced interventions like thrombolysis and vena cava filters.

Main Methods:

  • Review of existing literature on pulmonary embolism treatment guidelines and pharmacotherapies.

Related Experiment Videos

  • Comparative analysis of unfractionated heparin, LMWHs, novel oral anticoagulants, and vitamin K antagonists.
  • Discussion of interventional procedures such as embolectomy and vena cava filters.

    • Main Results:

    • LMWHs are replacing unfractionated heparin for initial PE treatment in most patients.
    • Thrombolytic drugs and embolectomy are reserved for massive, life-threatening PE.
    • Inferior vena cava filters are indicated for anticoagulation contraindications or failure.
    • New anticoagulants show potential but are not yet standard for initial PE treatment.
    • Long-term anticoagulation primarily uses vitamin K antagonists (e.g., warfarin) requiring regular monitoring (target INR 2.0-3.0).

    Conclusions:

    • LMWHs represent a preferred initial treatment for acute pulmonary embolism in standard clinical practice.
    • Warfarin remains the mainstay for long-term anticoagulation, necessitating careful monitoring.
    • Duration of anticoagulation varies based on PE etiology, from 3 months for reversible risk factors to 6-12 months for idiopathic PE.